GLP-1s: Biotech’s iPhone Moment

Up 215% Since 2021. Overlooked.

While headlines scream recession, biotech may be brewing the biggest opportunity since Bitcoin—its name is GLP-1s.

Since mid-2021, Eli Lilly, Novo Nordisk, and Viking Therapeutics have returned 215% on average—over 3x the S&P 500.